Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK, Synta Enter Oncology Alliance | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

GSK, Synta Enter Oncology Alliance

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline and Synta Pharmaceuticals Corp. have entered a global collaboration for the development and commercialization of STA-4783, a small-molecule oxidative stress inducer in Phase III development for the treatment of metastatic melanoma.

Under the terms of the agreement, the companies will share responsibility for development and commercialization of STA-4783 in the U.S. and GSK will be responsible for development and commercialization outside the U.S. Synta will receive an upfront payment of $80 million and is eligible to receive as much as $135 million for success-based milestones in metastatic melanoma, further development and regulatory milestones of as much as $450 million across various indications, and as much as $300 million in commercial milestone payments based on net sales.

Synta will continue to fund all development for metastatic melanoma in the U.S. and the companies will share development costs for STA-4783 in other indications both in the U.S. as well as costs outside of the U.S. Also, GSK may have the option to purchase as much as $45 million of Synta’s common stock based on the achievement of specified development and regulatory milestones.

“The data we have seen from the Phase II trials conducted by Synta have given us confidence in the potential of STA-4783 as a novel means of treating metastatic melanoma, a disease for which there is high unmet medical need,” said Moncef Slaoui, chairman R&D, GSK.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters